Trials / Completed
CompletedNCT00926016
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
Assessment of the Efficacy of Pioglitazone on Viral Kinetics, Cytokines, and Innate Immunity in a Group of Insulin Resistant, Treatment Naïve, Chronic Hepatitis C, Genotype 1 Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Brooke Army Medical Center · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
Detailed description
The aim of the study will be to determine if an insulin sensitizing thiazolidinedione (TZD) improves (1) baseline viremia, (2) enhances viral kinetics, (3) improves cytokine profiles and (4) up regulates innate cellular immunity (presumably adaptive immunity is up regulated as well) as measured by the bioactivity of the collected biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pioglitazone (Actos) | pioglitazone 45 mg a day |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2010-03-01
- Completion
- 2010-09-01
- First posted
- 2009-06-23
- Last updated
- 2012-02-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00926016. Inclusion in this directory is not an endorsement.